Emerging Trends of HIV Drug Resistance in Chinese HIV-Infected Patients Receiving First-Line Highly Active Antiretroviral Therapy: A Systematic Review and Meta-Analysis
Authors:
Open Access
- 22 July 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 59 (10) , 1495-1502
Abstract
Our study finds a rising trend of human immunodeficiency virus (HIV) drug resistance prevalence over longer durations of highly active antiretroviral therapy. China might face the danger of a new HIV epidemic generated by transmitted drug resistance. Background. Highly active antiretroviral therapy (HAART) has led to a dramatic decrease in AIDS-related morbidity and mortality through sustained suppression of human immunodeficiency virus (HIV) replication and reconstitution of the immune response. Settings like China that experienced rapid HAART rollout and relatively limited drug selection face considerable challenges in controlling HIV drug resistance (DR). Methods. We conducted a systematic review and meta-analysis to describe trends in emergent HIV DR to first-line HAART among Chinese HIV-infected patients, as reflected in the point prevalence of HIV DR at key points and fixed intervals after treatment initiation, using data from cohort studies and cross-sectional studies respectively. Results. Pooled prevalence of HIV DR from longitudinal cohorts studies was 10.79% (95% confidence interval [CI], 5.85%–19.07%) after 12 months of HAART and 80.58% (95% CI, 76.6%–84.02%) after 72 months of HAART. The HIV DR prevalence from cross-sectional studies was measured in treatment intervals; during the 0–12-month HAART treatment interval, the pooled prevalence of HIV DR was 11.1% (95% CI, 7.49%–16.14%), which increased to 22.92% at 61–72 months (95% CI, 9.45%–45.86%). Stratified analyses showed that patients receiving a didanosine-based regimen had higher HIV DR prevalence than those not taking didanosine (15.82% vs 4.97%). Patients infected through former plasma donation and those receiving AIDS treatment at village clinics had higher HIV DR prevalence than those infected through sexual transmission or treated at a county-level hospital. Conclusions. Our findings indicate higher prevalence of HIV DR for patients with longer cumulative HAART exposure, highlighting important subgroups for future HIV DR surveillance and control.Keywords
This publication has 31 references indexed in Scilit:
- Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in ChinaAIDS, 2013
- HIV Drug Resistance and Its Impact on Antiretroviral Therapy in Chinese HIV-Infected PatientsPLOS ONE, 2013
- Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort studyThe Lancet Infectious Diseases, 2011
- Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sitesTropical Medicine & International Health, 2010
- Predictors of Virologic Failure in HIV‐1–Infected Adults Receiving First‐Line Antiretroviral Therapy in 8 Provinces in ChinaClinical Infectious Diseases, 2010
- Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation CohortPLOS ONE, 2008
- Undue reliance on I 2 in assessing heterogeneity may misleadBMC Medical Research Methodology, 2008
- The Effect of Highly Active Antiretroviral Therapy on Mortality among HIV‐Infected Former Plasma Donors in ChinaClinical Infectious Diseases, 2008
- Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAARTPLOS Medicine, 2006
- Web Resources for HIV Type 1 Genotypic-Resistance Test InterpretationClinical Infectious Diseases, 2006